India Globalization Capital Inc. (NYSEAMERICAN: IGC)  jumped 11.49% after the company announced the completion of Cohort 3 of phase 1 clinical study on its tetrahydrocannabinol  (THC)-based experimental new drug, IGC-ADI, for alleviating Alzheimer’s disease symptoms.  FDA had approved IGC-ADI for Phase 1 study  The company previously disclosed that it had […]